ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.97
0.86%
US Tech 100
21,169.20
1.21%
S&P 500
6,061.64
0.59%
US Dollar vs CAD
1.43235
0.19%
Bitcoin
97,357.36
0.90%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) News

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HOTH
DateTimeSourceHeadlineSymbolCompany
02/10/20257:22AMPR Newswire (US)Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
02/07/20253:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
02/07/20253:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
01/24/20253:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
01/24/20257:29AMPR Newswire (US)Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNASDAQ:HOTHHoth Therapeutics Inc
01/21/20257:29AMPR Newswire (US)Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent ApplicationsNASDAQ:HOTHHoth Therapeutics Inc
01/17/20257:29AMPR Newswire (US)Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025NASDAQ:HOTHHoth Therapeutics Inc
01/15/20253:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
01/08/202512:27PMPR Newswire (US)Hoth Therapeutics Responds to Market Rumors and Shareholder InquiriesNASDAQ:HOTHHoth Therapeutics Inc
01/07/202511:35AMAllPennyStocks.comShares Of This Micro Cap More Than Doubled TodayNASDAQ:HOTHHoth Therapeutics Inc
01/07/20257:29AMPR Newswire (US)Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin ToxicitiesNASDAQ:HOTHHoth Therapeutics Inc
12/26/20246:58AMPR Newswire (US)Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
12/02/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
11/20/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
11/20/20246:38AMPR Newswire (US)Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:HOTHHoth Therapeutics Inc
11/12/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
11/08/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
11/01/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
10/29/202411:43AMPR Newswire (US)Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyNASDAQ:HOTHHoth Therapeutics Inc
10/15/20245:38AMPR Newswire (US)Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now UnderwayNASDAQ:HOTHHoth Therapeutics Inc
09/17/20246:57AMPR Newswire (US)Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
09/05/20249:32AMPR Newswire (US)Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a TrialNASDAQ:HOTHHoth Therapeutics Inc
09/05/20247:03AMPR Newswire (US)Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001NASDAQ:HOTHHoth Therapeutics Inc
08/21/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/21/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/21/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/21/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/16/20243:15PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOTHHoth Therapeutics Inc
08/15/20247:04AMPR Newswire (US)Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
08/09/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOTH

Your Recent History

BMF
DITN30
DITN30 - 07/2030
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads